Drug class
While "Plasma Kallikrein Inhibitor, Recombinant Monoclonal Antibody" is a descriptive mechanistic and structural categorization rather than a standalone FDA Established Pharmacologic Class (the official FDA pharmacologic class is simply "plasma kallikrein inhibitor"), it describes fully human monoclonal antibodies engineered to bind and inhibit plasma kallikrein. Read more about Plasma Kallikrein Inhibitor, Recombinant Monoclonal Antibody
4 drugs in this class 4 manufacturers
While "Plasma Kallikrein Inhibitor, Recombinant Monoclonal Antibody" is a descriptive mechanistic and structural categorization rather than a standalone FDA Established Pharmacologic Class (the official FDA pharmacologic class is simply "plasma kallikrein inhibitor"), it describes fully human monoclonal antibodies engineered to bind and inhibit plasma kallikrein.
By blocking active plasma kallikrein, these agents prevent the enzymatic cleavage of high-molecular-weight kininogen into bradykinin, a potent vasodilator and mediator of vascular permeability.
Therapeutically, this mechanism is indicated for routine prophylaxis to prevent swelling attacks in patients with hereditary angioedema.
While "Plasma Kallikrein Inhibitor, Recombinant Monoclonal Antibody" is a descriptive mechanistic and structural categorization rather than a standalone FDA Established Pharmacologic Class (the official FDA pharmacologic class is simply "plasma kallikrein inhibitor"), it describes fully human monoclonal antibodies engineered to bind and inhibit plasma kallikrein Therapeutically, this mechanism is indicated for routine prophylaxis to prevent swelling attacks in patients with hereditary angioedema
While "Plasma Kallikrein Inhibitor, Recombinant Monoclonal Antibody" is a descriptive mechanistic and structural categorization rather than a standalone FDA Established Pharmacologic Class (the official FDA pharmacologic class is simply "plasma kallikrein inhibitor"), it describes fully human monoclonal antibodies engineered to bind and inhibit plasma kallikrein
By blocking active plasma kallikrein, these agents prevent the enzymatic cleavage of high-molecular-weight kininogen into bradykinin, a potent vasodilator and mediator of vascular permeability
By blocking active plasma kallikrein, these agents prevent the enzymatic cleavage of high-molecular-weight kininogen into bradykinin, a potent vasodilator and mediator of vascular permeability
Therapeutically, this mechanism is indicated for routine prophylaxis to prevent swelling attacks in patients with hereditary angioedema
Following a drug class requires a free Physicians Office Resource account.
